Logo der Deutsch Industrie- und Handelskammer in Japan

Japanese German Symposium on Medical Biotechnology

  • Event

21 October 2026 | Symposium | Congrès Square Grand Green Osaka, Park Hall 1 & 2

7f64efcd-9a03-410e-8a3d-10f1f668fa1f.jpg
iStock / nicolas

This symposium brings together leading German and Japanese companies, research institutions, and public-sector stakeholders in the field of medical biotechnology to exchange practical insights and explore opportunities for collaboration. The programme will highlight key developments in areas including biopharmaceuticals, cell and gene therapies, regenerative medicine and cell technologies, in vitro diagnostics, personalised medicine, biomanufacturing and process automation, as well as digital health.

 

With a strong focus on business dialogue, the symposium provides a platform to connect with industry peers, explore potential partnerships, and discuss the policy and technological trends shaping the market.

 

The symposium aims to strengthen bilateral exchange and foster concrete cooperation by bringing together decision-makers and experts from government, academia, and industry in Japan and Germany.

 

Held within the framework of the German Federal Ministry for Economic Affairs and Energy (BMWE) Market Entry Programme, the symposium is aimed at organisations and businesses active in medical biotechnology, pharmaceuticals, diagnostics, biomanufacturing, and digital health. It forms part of a business delegation of German SMEs visiting Japan from 19 to 23 October 2026 and is designed to facilitate targeted exchange as well as potential business and research partnerships with Japanese stakeholders.

 

Participation is subject to specific conditions.

  • Participation Fee

    Free of charge

  • Wednesday 21 October 2026

    10:00 Uhr ‐ 13:35 Uhr (JST) | Registration: 9:30

Programme

 

*The programme is subject to change without notice.

Remarks

Participation fee: Free
Language: English-Japanese simultaneous translation

Participation Notes

  • Registration will be accepted on a first-come, first-served basis and will close once the capacity of 80 participants is reached.
  • To ensure relevant and productive discussions, participation is intended for professionals with a clear connection to the industry.
  • If needed, we may contact you to request additional details regarding your interests to help ensure the best possible match and discussions.
  • For smooth check-in, please bring two business cards for registration.
  • Please note that registration is for the symposium program and does not apply to the networking lunch only.

Organisers

A Program of

German Federal Ministry for Economic Affairs and Energy

 

Organised by

German Chamber of Commerce and Industry in Japan (AHK Japan)

 

Co-Organised by

Kansai Bureau of Economy, Trade and Industry (METI-KANSAI)

 

Supported by

Berlin Partner of Economics and Technology GmbH

biosaxony e.V.

medways e.V.

Participating Companies

TQ Therapeutics GmbHTQ Therapeutics develops a hybrid in vivo CAR-T platform enabling ultra-fast six-hour cell therapy processing (EXiVO) at the point of care. The CELLfinity platform enables modular generation of infinite CGT clinical programmes for scalable, accessible autologous mRNA T-cell therapeutics across indications. The process is enabled by TQx’s affinity/column-based T-cell selection technology for CD3+ T-cell isolation from whole blood.
faCellitate GmbHfaCellitate GmbH develops synthetic, chemically defined surface coatings for advanced tissue models, stem cell research and cell therapy. Built on a proprietary biomimetic materials platform, the company’s BIOINSTRUCT™ technology enables robust and reproducible iPSC culture without animal-derived components. Originating from BASF research, faCellitate is advancing scalable solutions that support the development and manufacturing of next-generation regenerative medicines and cell-based therapies.
VitrofluidiX GmbHVitrofluidiX is a biotechnology start-up based in Cologne, Germany, developing the first fully integrated, modular and chip-agnostic organ-on-a-chip platform. VitroFlow standardises organ-on-a-chip experiments by integrating incubation, perfusion and environmental control into a single bench-top system while remaining compatible with chips from different manufacturers. The platform is designed to work seamlessly with standard laboratory microscopes, enabling live imaging and real-time experiment monitoring without additional equipment. By combining full integration with an open, adaptable architecture, VitroFlow makes organ-on-a-chip technology more accessible, reproducible and scalable for biomedical research, drug development and future standardised workflows.
GliTTher GmbHGliTTher GmbH aims to improve treatment outcomes for glioblastoma, the most aggressive brain tumour and an orphan disease with a high unmet medical need. The disease often affects people in mid-life, and the five-year survival rate has remained at around 5% since 2005. GliTTher targets treatment-resistant glioma-initiating cells (GICs), a self-renewing subpopulation widely implicated as a driver of tumour recurrence. The company’s proprietary small molecules are paired with a companion diagnostic for patient stratification and delivered locally at the resection site. Its human-relevant preclinical platform is designed to reduce development risks and accelerate clinical entry. GliTTher seeks strategic pharmaceutical and institutional partners with CNS oncology pipelines to collaborate on grants (e.g. Horizon Europe), clinical development, regulatory navigation and commercialisation.
CO.DON GmbHCO.DON GmbH is a German regenerative medicine company specialising in biological cartilage repair. Its lead product, Spherox, is the only EMA-approved cell therapy for articular cartilage defects of the knee, with potential future applications in other joints. Building on extensive European clinical experience, specialised GMP manufacturing and a strong network of orthopaedic and sports medicine experts, co.don is expanding international partnerships in regenerative medicine. ReLive Life Sciences, its Boston-based parent company, is leading US market development. In Japan, co.don seeks partners for regulatory development, clinical collaboration, commercialisation and innovation in cartilage and osteochondral repair.
Axiom Insights GmbHAxiom Insights is a deep-tech start-up providing an X-Ray Fluorescence Imaging (XFI) platform that leverages high-brilliance synchrotron radiation for advanced imaging capabilities. XFI enables quantitative biodistribution mapping of entities of interest such as cells, biomolecules and medical drugs in vivo. This capability is particularly valuable in preclinical drug development, where quantitative information on drug distribution and kinetics within the body is essential. XFI combines high spatial resolution, quantitative precision and low radiation exposure, enabling Axiom Insights to offer non-invasive pharmacokinetic services that can reduce the number of test animals and accelerate drug development.
MedSkin Solutions Dr. Suwelack AGMedSkin Solutions Dr. Suwelack AG is a German life sciences company specialising in regenerative medicine and advanced wound care. Drawing on decades of expertise in tissue regeneration and its proprietary Advanced CryoSafe® Method, the company develops and manufactures clinically focused technologies that support the body’s natural regenerative capacity. Its MedCare division offers solutions including MatriDerm® and ProHeal®, while its Industry Solutions/CDMO business partners with medical device companies to develop regenerative biomaterials, private-label products and finished medical devices. Its collagen-based platforms support the regeneration, augmentation and reconstruction of soft, hard and load-bearing tissues, with the aim of improving patient outcomes and quality of life.

Registrierungsformular

Dieses Formular wird von SuperOffice (online.superoffice.com) generiert. Wenn das Formular nicht angezeigt wird, ändern Sie bitte die Einstellungen Ihrer Datenschutzeinstellungen. Außerdem ist dieses Formular im Internet Explorer nicht verfügbar.

Disclaimer ©2026 German Chamber of Commerce and Industry in Japan (AHK Japan). No part of this presentation may be reproduced without prior permission. While every reasonable effort is made to ensure that the information provided is accurate, no guarantees for the currency or accuracy of information are made. All material relating to information, products and services (or to third party information, products and services), is provided 'as is', without any representation or endorsement made and without warranty of any kind, including the implied warranties of satisfactory quality, fitness for a particular purpose, non-infringement, compatibility, security and accuracy. The speakers are solely responsible for the content thereof; In no event will the organizer and/or the speakers be liable for any loss or damage whatsoever arising from infringement or any defect of rights of the content of the presentation. Views expressed are not necessarily those of AHK Japan. All our events follow Chatham House Rules.

Ansprechpartner

In den Kategorien:

Die neuesten Veranstaltungen ansehen

Alle Veranstaltungen ansehen
  • AI Symposium
    Veranstaltung

    Symposium: Beyond the Hype: Making AI Work

    30 September 2026 | Symposium | Europa House

  • 261001-YPF-Fall-Speed-Networking.png
    Veranstaltung

    Kansai Young Professionals Forum: Fall Speed Networking

    1 October 2026 | Joint Chamber | Grand Green Osaka

  • AdobeStock_370522308.jpeg
    Veranstaltung

    Shaping the Future Together: Building Long-term Customer Partnerships

    13 November 2026 | Working Group | AHK Japan

Suchen Sie etwas Anderes?

In unserem Informationszentrum finden Sie aktuelle Neuigkeiten, Downloads, Videos, Podcasts...

Zum Info Hub